Sarah Cannon Research Institute shared a post on LinkedIn about a recent article by Veronique Dieras at al, published in Journal of Clinical Oncology:
“New Research Alert from Sarah Cannon Research Institute
We’re proud to share the latest publication in Journal of Clinical Oncology: HER2CLIMB-05, a Phase 3 study evaluating tucatinib in combination with trastuzumab and pertuzumab as first-line maintenance therapy for HER2+ metastatic breast cancer. This research underscores the potential of tucatinib as an option for first-line maintenance therapy in HER2+ MBC.
Kudos to Erika Hamilton and our incredible team at SCRI Oncology Partners and across the network for advancing care for patients with HER2+ metastatic breast cancer.”
Title: HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer
Authors: Veronique Dieras, Giuseppe Curigliano, Miguel Martin, Florence Lerebours, Junji Tsurutani, Marie-France Savard, Katarzyna J. Jerzak, Xichun Hu, Luciana Carla Martins de Aquino Pimentel, Ciara C. O’Sullivan, Eriko Tokunaga, Alicia Okines, Chiun-Sheng Huang, William Jacot, Joohyuk Sohn, Eduardo Cronemberger Silva, Volkmar Mueller, Shan Yang, Giovanna Granata, Qi Shen, Libero Santarpia, Erika Hamilton
Read the Full Article on Journal of Clinical Oncology
More posts about Sarah Cannon Research Institute.